| 1. Zhong S, Wang G, Qin X, Li Y, Sun B, Kong FM, Gao Y, Jin JY.A Statistical Approach to Assess Biological Equivalent Mean Organ Dose (MOD) for Different Fractionations in Thoracic Radiotherapy.Biomedicines.2025.13（5）.1110.SCI（含SCIE） |
| 2. Chen F, Zhou P, Ren G, Lee EKW, Liu Q, Shen Y, Wang Y, El Helali A, Jin JY, Fu P, Dai W, Lee AWM, Yu H, Spring Kong FM.Interpretable deep learning insights: Unveiling the role of 1 Gy volume on lymphopenia after radiotherapy in breast cancer.radiotherapy and oncology.2024.197:110333..197:110333..SCI（含SCIE） |
| 3. Jin JY, Yuan J, Qin X, Li Y, Yan H, Oleinick NL, Yao M, Pan Q, Kong FS, Machtay M. .Derivation of a comprehensive semi-empirical proton RBE model from published experimental cell survival data collected in the PIDE database.Front Oncol..2024.14.14:1415213.SCI（含SCIE） |
| 4. Zhang J, Yang L, Li H, Chan JW, Lee EKW, Liu M, Ma L, Liu Q, Jin JY, Fu P, Xu Z, Kong FS..Dosimetric Effect of Thymus and Thoracic Duct on Radiation-Induced Lymphopenia in Patients With Primary Lung Cancer Who Received Thoracic Radiation.advanced radiation oncology.2023.8（6）.101260.SCI（含SCIE） |
| 5. Jian-Yue Jin.Prospect of radiotherapy technology development in the era of immunotherapy.Journal of the National Cancer Center,.2022.2（2）.106-112.SCI（含SCIE） |
| 6. H Yu, F Chen, KO Lam, L Yang, Y Wang, JY Jin, A Ei Helali, FM Kong.Potential Determinants for Radiation-Induced Lymphopenia in Patients With Breast Cancer Using Interpretable Machine Learning Approach..Front Immunol.2022.13.10.3389/fimmu.2022.768811.SCI（含SCIE） |
| 7. Fang Chen 1 2, Jian-Yue Jin 3, Timothy S K Hui 1, Haiman Jing 1, Hong Zhang 4, Yaqing Nong 1, Ying Han 1, Weili Wang 3, Lingyu Ma 1, Fan Yi 1, Qingqing Chen 1, Yongsheng Zhang 1, Pingfu Fu 5, Li Yang 1, Zhiyuan Xu 1, Feng-Ming Spring Kong 1 2.Radiation Induced Lymphopenia Is Associated With the Effective Dose to the Circulating Immune Cells in Breast Cancer.Front Oncol.2022.12.10.3389/fonc.2022.768956..SCI（含SCIE） |
| 8. .Risk factors for radiation induced lymphopenia in patients with breast cancer receiving adjuvant radiotherapy..Ann Transl Med.2021.9(16).1288. |
| 9. .Monte Carlo Dose Calculation Using MRI Based Synthetic CT Generated by Fully Convolutional Neural Network for Gamma Knife Radiosurgery.Technol Cancer Res Treat..2021. .doi: 10.1177/1533033821104643. |
| 10. .Impact of effective dose to immune cells (EDIC) on lymphocyte nadir and survival in limited-stage SCLC.Radiother Oncol..2021.162.26-33. |
| 11. .Higher Radiation Dose to the Immune Cells Correlates with Worse Tumor Control and Overall Survival in Patients with Stage III NSCLC: A Secondary Analysis of RTOG0617..Cancers (Basel)..2021.13(24).6193，10.3390/cancers13246193. |
| 12. .Weighted-Support Vector Machine Learning Classifier of Circulating Cytokine Biomarkers to Predict Radiation-Induced Lung Fibrosis in Non-Small-Cell Lung Cancer Patients.Front Oncol.2020. .DOI: 10.3389/fonc.2020.601979. |
| 13. .Ultra-High Dose Rate Effect on Circulating Immune Cells: A Potential Mechanism for FLASH Effect?.Radiother Oncol..2020.149.55-62. |
| 14. .The impact of the effective dose to immune cells on lymphopenia and survival of esophageal cancer after chemoradiotherapy..Radiother Oncol..2020.146.180-186. |
| 15. .Risk factors for symptomatic radiation pneumonitis after stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer..Radiother Oncol..2020.156.231-238. |
| 16. .Patient-Specific Lymphocyte Loss Kinetics as Biomarker of Spleen Dose in Patients Undergoing Radiation Therapy for Upper Abdominal Malignancies.Advances in Radiation Oncology.2020.6(1).100545. |
| 17. .Lymphopenia and radiation dose to circulating lymphocyte with neoadjuvant chemoradiation in esophageal squamous cell carcinoma.Advances in Radiation Oncology.2020.5(5).880-888. |
| 18. .Comprehensive Analysis of the Kinetics of Radiation-Induced Lymphocyte Loss in Patients Treated with External Beam Radiation Therapy.Radiat Res.2020.193(1).73-81.. |
| 19. .Central Airway Toxicity After High Dose Radiation: A Combined Analysis of Prospective Clinical Trials for Non-Small Cell Lung Cancer.Int J Radiat Oncol Biol Phys..2020.108(3).587-596. |
